Jazz Pharmaceuticals Plc (JAZZ)
241.55
+1.18
(+0.49%)
USD |
NASDAQ |
Nov 13, 16:00
241.57
+0.02
(+0.01%)
Pre-Market: 19:59
Jazz Pharmaceuticals Net Income (Quarterly) : -483.40M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -483.40M |
| June 30, 2026 | 192.80M |
| March 31, 2026 | 293.10M |
| December 31, 2025 | 203.45M |
| September 30, 2025 | 251.41M |
| June 30, 2025 | -718.47M |
| March 31, 2025 | -92.54M |
| December 31, 2024 | 191.12M |
| September 30, 2024 | 215.06M |
| June 30, 2024 | 168.57M |
| March 31, 2024 | -14.62M |
| December 31, 2023 | 94.15M |
| September 30, 2023 | 146.82M |
| June 30, 2023 | 104.44M |
| March 31, 2023 | 69.42M |
| December 31, 2022 | -240.72M |
| September 30, 2022 | -19.65M |
| June 30, 2022 | 34.66M |
| March 31, 2022 | 1.647M |
| December 31, 2021 | -35.35M |
| September 30, 2021 | -52.83M |
| June 30, 2021 | -363.32M |
| March 31, 2021 | 121.83M |
| December 31, 2020 | 133.41M |
| September 30, 2020 | 148.23M |
| Date | Value |
|---|---|
| June 30, 2020 | 114.80M |
| March 31, 2020 | -157.83M |
| December 31, 2019 | 73.99M |
| September 30, 2019 | 102.28M |
| June 30, 2019 | 261.90M |
| March 31, 2019 | 85.20M |
| December 31, 2018 | 159.47M |
| September 30, 2018 | 149.32M |
| June 30, 2018 | 92.32M |
| March 31, 2018 | 45.99M |
| December 31, 2017 | 232.21M |
| September 30, 2017 | 63.53M |
| June 30, 2017 | 105.60M |
| March 31, 2017 | 86.51M |
| December 31, 2016 | 116.69M |
| September 30, 2016 | 89.83M |
| June 30, 2016 | 114.50M |
| March 31, 2016 | 75.81M |
| December 31, 2015 | 82.76M |
| September 30, 2015 | 87.96M |
| June 30, 2015 | 88.11M |
| March 31, 2015 | 70.70M |
| December 31, 2014 | 81.61M |
| September 30, 2014 | 25.77M |
| June 30, 2014 | 43.59M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Avadel Pharmaceuticals Plc | 0.02M |
| GH Research Plc | -15.15M |
| Cosmo NV | -- |
| Corcept Therapeutics, Inc. | 124.49M |
| Eli Lilly & Co. | 6.451B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.243B |
| Total Expenses (Quarterly) | 1.726B |
| EPS Diluted (Quarterly) | -7.471 |
| Enterprise Value | 18.27B |
| Gross Profit Margin (Quarterly) | 77.28% |
| Profit Margin (Quarterly) | -38.89% |
| Earnings Yield | 1.22% |
| Operating Earnings Yield | 7.34% |
| Normalized Earnings Yield | 5.124 |